Ly-2127399

PurposeLY3022859 is an anti-TGFβRII IgG1 monoclonal antibody that inhibits receptor-mediated signaling activation. The primary… Expand

B‐cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an… Expand

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises several clinical entities with diverse clinical… Expand

The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the… Expand

Background Patients with rheumatoid arthritis (RA) exhibit substantial variability in both the magnitude and duration of their… Expand

For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment… Expand

8012 Background: LY2127399 (LY) is a human mAb that neutralizes membrane-bound and soluble B cell activating factor (BAFF). LY… Expand

Myeloma bone disease (BD) not only impairs quality of life, but is also associated with impaired survival. Studies of the biology… Expand

Treating multiple sclerosis (MS) with monoclonal antibodies (mAbs) has been marked by both progress and setbacks in the past 2… Expand